Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17850607 | 0.90 | ALDH1A1 (0.46) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL4613472 | 0.83 | ALDH1A1 (0.58) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL17527131 | 0.83 | TSHR (0.49) | ALDH1A1L3MBTL1TSHRGAARAB9A | |
| SCHEMBL8353377 | 0.83 | TSHR (0.53) | ALDH1A1L3MBTL1TSHRGAARAB9A | |
| SCHEMBL17850623 | 0.81 | TSHR (0.55) | ALDH1A1L3MBTL1TSHRGAARAB9A | |
| SCHEMBL13135936 | 0.81 | HTT (0.52) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL14223107 | 0.81 | L3MBTL1 (0.51) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL6231400 | 0.80 | TSHR (0.53) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL19151104 | 0.79 | HTT (0.53) | GLAALDH1A1L3MBTL1HTTTSHR | |
| SCHEMBL13380094 | 0.77 | HTT (0.47) | GLAALDH1A1L3MBTL1HTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022782-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | GLA 1215/4885ALDH1A1 2644/4885L3MBTL1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.